[O18] Oral Session 18　Gastrointestinal Cancer 3（Lower GI Tract-Colorectal Cancer 2）
【E】

[O18-4] Exploratory Biomarker Analysis of Trastuzumab Deruxtecan in HER2-Expressing Metastatic Colorectal Cancer (DESTINY-CRC01)

^○Kensei Yamaguchi¹, Salvatore Siena², Kanwal Raghav³, Toshiki Masuishi⁴, Tomohiro Nishina⁵, Elena Elez⁶, Javier Rodriguez⁷, Ian Chau⁸, Maria Di Bartolomeo⁹, Hisato Kawakami¹⁰, Fumitaka Suto¹¹, Kojiro Kobayashi¹¹, Makito Koga¹², Koichiro Inaki¹², Yusuke Kuwahara¹², Issey Takehara¹², Axel Grothey¹³, Takayuki Yoshino¹⁴ (1.The Cancer Institute Hospital of JFCR, Tokyo, Japan, 2.Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy, 3.Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 4.Aichi Cancer Center Hospital, Aichi, Japan, 5.National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, 6.Hospital Universitari Vall d’Hebron Institite of Oncology (VHIO), Barcelona, Spain, 7.Clinica Universidad de Navarra, Navarra, Spain, 8.Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, 9.Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, 10.Kindai University Hospital, Osaka, Japan, 11.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 12.Daiichi Sankyo, Co., Ltd., Tokyo, Japan, 13.West Cancer Center, Germantown, TN, USA, 14.National Cancer Center Hospital East, Kashiwa, Japan)